Spelling suggestions: "subject:"myocardial ischemia/therapy"" "subject:"nyocardial ischemia/therapy""
1 |
Resultados do tratamento fibrinolítico da trombose venosa iliacofemoral por infusão seletiva de rt-PA em baixas doses / Results of fibrinolytic treatment of iliofemoral deep vein thrombosis by selective infusion of low-dose rt-PACasella, Ivan Benaduce 07 December 2004 (has links)
INTRODUÇÃO: A trombose venosa profunda é uma doença de alta incidência, e uma das principais causas de insuficiência venosa profunda. O tratamento clássico, com heparina e anticoagulante oral, não tem ação direta sobre o tempo de remoção do trombo. O tratamento trombolítico seletivo por cateter permite rápida remoção do coágulo com complicações inferiores a administração sistêmica do fibrinolítico. OBJETIVO: Comprovar a eficácia da infusão seletiva de rt-PA em baixas doses no tratamento da trombose venosa profunda iliacofemoral aguda e na prevenção do desenvolvimento dos sinais, sintomas e alterações hemodinâmicas tardios relacionados à síndrome pós-trombótica.METODO: Em pacientes portadores de trombose venosa profunda iliacofemoral aguda, implantou-se um cateter reto multiperfurado no segmento venoso acometido, e infundiuse dose contínua de 1,0 mg/hora de rtPA diluído. O controle do procedimento foi feito por flebografia transcateter a cada 12-18h. RESULTADOS: Quinze pacientes foram selecionados. Houve fibrinólise efetiva em 12 dos 15 casos (80%), com restabelecimento da perviedade iliacofemoral. O tempo médio de infusão do rt-PA foi de 41 horas. Houve correlação entre o grau de fibrinólise e a magnitude da melhora clínica (p < 0,05). Não ocorreram complicações maiores, tais como embolia pulmonar ou hemorragias graves. Quatro pacientes apresentaram episódios de retrombose. O grupo foi seguido por um período de 45 a 131 semanas (mediana de 99). Nos oito pacientes em que a fibrinólise foi efetiva e não houve retrombose, a incidência de seqüelas clínicas e de refluxo valvular venoso ao duplex-scan foi inferior a observada nos sete pacientes com falha terapêutica ou retrombose (p < 0,01 nas duas amostras). A diferença na incidência de recanalização venosa completa também foi estatisticamente significativa (p < 0,05) em favor do grupo com fibrinólise efetiva. CONCLUSÕES: A terapêutica trombolítica seletiva com rt-PA em baixas doses é eficaz e segura no tratamento agudo da trombose venosa iliacofemoral. A evolução clínica e ultrassonográfica tardia foram significativamente superiores nos pacientes em que a terapêutica foi efetiva / INTRODUCTION: Deep venous thrombosis keeps being a high incidence disease and one of the leading causes of chronic venous insufficiency. The classic therapy with heparin and oral anticoagulation doesn\'t have direct action over thrombus removal time. Seletive catheter-directed thrombolysis allows an early thrombus removal with a lower rate of complications than systemic thrombolysis. OBJECTIVES: To prove the efficacy of catheterdirected low-dose rt-PA infusion in the treatment of acute iliofemoral deep vein thrombosis and in the prevention of late clinical and haemodinamic sequelae of post-thrombotic syndrome. METHODS: In selected patients with acute iliofemoral deep venous thrombosis, a straight multiside-hole catheter was introduced through the thrombotic venous segments. A low-dose (1mg/h) rt-PA continuous infusion was initiated and control transcatheter phlebography was taken every 12-18 hours. RESULTS: Fifteen patients were selected. Effective fibrinolysis was achieved in 12 of 15 cases (80%), with iliofemoral patency obtained. The medium time of rt-PA infusion was 41 hours. Statistic correlation between lysis grade and clinical improvement was observed (p < 0,05). There were no episodes of major complications such as transfusion-needed hemorrhage or pulmonary embolism. Four patients presented with rethrombosis. The group was followed by a period of 45 to 131 weeks (median 99). In the eight patients in witch lytic therapy was well succeeded and venous patency was kept, the incidence of clinical signs and symptoms of venous insufficiency and duplex-scan findings of valvular reflux was statistically lower than in the seven patients with acute therapeutic failure or rethrombosis (p < 0,01 for both). There was also difference in findings of complete venous recanalization between the two groups (p < 0,05), showing benefit to the group with effective therapy. CONCLUSIONS: Low-dose rt-PA fibrinolytic therapy is safe and effective in the treatment of iliofemoral acute venous thrombosis. The clinical and ultrasound late evolution was superior in patients in witch lytic therapy was effective
|
2 |
Resultados do tratamento fibrinolítico da trombose venosa iliacofemoral por infusão seletiva de rt-PA em baixas doses / Results of fibrinolytic treatment of iliofemoral deep vein thrombosis by selective infusion of low-dose rt-PAIvan Benaduce Casella 07 December 2004 (has links)
INTRODUÇÃO: A trombose venosa profunda é uma doença de alta incidência, e uma das principais causas de insuficiência venosa profunda. O tratamento clássico, com heparina e anticoagulante oral, não tem ação direta sobre o tempo de remoção do trombo. O tratamento trombolítico seletivo por cateter permite rápida remoção do coágulo com complicações inferiores a administração sistêmica do fibrinolítico. OBJETIVO: Comprovar a eficácia da infusão seletiva de rt-PA em baixas doses no tratamento da trombose venosa profunda iliacofemoral aguda e na prevenção do desenvolvimento dos sinais, sintomas e alterações hemodinâmicas tardios relacionados à síndrome pós-trombótica.METODO: Em pacientes portadores de trombose venosa profunda iliacofemoral aguda, implantou-se um cateter reto multiperfurado no segmento venoso acometido, e infundiuse dose contínua de 1,0 mg/hora de rtPA diluído. O controle do procedimento foi feito por flebografia transcateter a cada 12-18h. RESULTADOS: Quinze pacientes foram selecionados. Houve fibrinólise efetiva em 12 dos 15 casos (80%), com restabelecimento da perviedade iliacofemoral. O tempo médio de infusão do rt-PA foi de 41 horas. Houve correlação entre o grau de fibrinólise e a magnitude da melhora clínica (p < 0,05). Não ocorreram complicações maiores, tais como embolia pulmonar ou hemorragias graves. Quatro pacientes apresentaram episódios de retrombose. O grupo foi seguido por um período de 45 a 131 semanas (mediana de 99). Nos oito pacientes em que a fibrinólise foi efetiva e não houve retrombose, a incidência de seqüelas clínicas e de refluxo valvular venoso ao duplex-scan foi inferior a observada nos sete pacientes com falha terapêutica ou retrombose (p < 0,01 nas duas amostras). A diferença na incidência de recanalização venosa completa também foi estatisticamente significativa (p < 0,05) em favor do grupo com fibrinólise efetiva. CONCLUSÕES: A terapêutica trombolítica seletiva com rt-PA em baixas doses é eficaz e segura no tratamento agudo da trombose venosa iliacofemoral. A evolução clínica e ultrassonográfica tardia foram significativamente superiores nos pacientes em que a terapêutica foi efetiva / INTRODUCTION: Deep venous thrombosis keeps being a high incidence disease and one of the leading causes of chronic venous insufficiency. The classic therapy with heparin and oral anticoagulation doesn\'t have direct action over thrombus removal time. Seletive catheter-directed thrombolysis allows an early thrombus removal with a lower rate of complications than systemic thrombolysis. OBJECTIVES: To prove the efficacy of catheterdirected low-dose rt-PA infusion in the treatment of acute iliofemoral deep vein thrombosis and in the prevention of late clinical and haemodinamic sequelae of post-thrombotic syndrome. METHODS: In selected patients with acute iliofemoral deep venous thrombosis, a straight multiside-hole catheter was introduced through the thrombotic venous segments. A low-dose (1mg/h) rt-PA continuous infusion was initiated and control transcatheter phlebography was taken every 12-18 hours. RESULTS: Fifteen patients were selected. Effective fibrinolysis was achieved in 12 of 15 cases (80%), with iliofemoral patency obtained. The medium time of rt-PA infusion was 41 hours. Statistic correlation between lysis grade and clinical improvement was observed (p < 0,05). There were no episodes of major complications such as transfusion-needed hemorrhage or pulmonary embolism. Four patients presented with rethrombosis. The group was followed by a period of 45 to 131 weeks (median 99). In the eight patients in witch lytic therapy was well succeeded and venous patency was kept, the incidence of clinical signs and symptoms of venous insufficiency and duplex-scan findings of valvular reflux was statistically lower than in the seven patients with acute therapeutic failure or rethrombosis (p < 0,01 for both). There was also difference in findings of complete venous recanalization between the two groups (p < 0,05), showing benefit to the group with effective therapy. CONCLUSIONS: Low-dose rt-PA fibrinolytic therapy is safe and effective in the treatment of iliofemoral acute venous thrombosis. The clinical and ultrasound late evolution was superior in patients in witch lytic therapy was effective
|
3 |
Reconstitution of coronary vasculature by an active fraction of geum japonicum in ischemic rat hearts and the underlying mechanisms. / CUHK electronic theses & dissertations collectionJanuary 2010 (has links)
Coronary heart diseases (CHD) remain the most prevalent cause of premature death. Ischemic hearts often result from coronary vasculature occlusion. Significant efforts have been made for the treatment of CHD, including medications and surgical procedures. Currently there are still no effective drugs or therapeutics available for the treatment of the disease. Growing new coronary vessels to naturally bypass narrowed/occluded arteries or forming sufficient collaterals to the ischemic region would lead to substantially improved blood perfusion and correction of ischemia. However, this aim remains a theoretical ideal due to the negligible ability to grow new coronary vessels even with current advances in therapeutic angiogenesis. In the present study, we have isolated and identified an active fraction of Geum japonicum (AFGJ) showing significant activity in induction of efficient coronary angiogenesis and heart function improvement. / In addition, proteomics methods were applied to investigate the protein alterations in CHD ischemic hearts and HUVECs. Two dimensional polyacrylamide gel electrophoresis (2-D PAGE) of the heart tissues of CHD rats showed 16 differentially expressed spots compared with sham and vehicle hearts, of which 8 were identified. Furthermore, 11 identified proteins of HUVECs treated with AFGJ or Angio-G at different time points were also observed by 2-D PAGE. The majority of identified proteins was found to be involved in the process of energy metabolisms. / In conclusion, these results have demonstrated therapeutic properties of AFGJ to induce early reconstitution of damaged coronary vasculature through both angiogensis and vasculogenesis. AFGJ treatments may provide a novel therapeutic modality for effective treatment of ischemic heart diseases. / The therapeutic effect of AFGJ on CHD through reconstitution of partially occluded coronary vessels in CHD animal models was demonstrated with underlying signaling mechanisms identified. Briefly, AFGJ could promote the proliferation of human umbilical vein endothelial cells (HUVECs) in vitro and the growth of new blood vessels or coronary collaterals in CHD models after 2-week treatment. The number of newly formed coronary vessels in treated hearts was more than that of vehicle treated hearts, as indicated by both MicroCT and histology analysis. Echocardiography studies demonstrated significant improvement of heart functions 2 weeks after treatment with AFGJ. Furthermore, ECG measurements showed that the altered ST segment in AFGJ treated CHD models almost had full recovery to a normal level while rats in the vehicle group consistently suffered from heart ischemia. Moreover, the results of MicroCT reconstruction directly demonstrated the reconstitution of the damaged coronary vessels with newly formed functional coronary collaterals, as illustrated by more blood vessels density (AFGJ vs vehicle [%]: 4.5+/-0.5 vs 2+/-0.35) and more branching points (AFGJ vs vehicle: 0.94+/-0.07 vs 0.65+/-0.10). These data suggest that AFGJ treatment significantly corrects the ischemia of the affected regions of the heart. / We also explored possible mechanisms underlying the effect of AFGJ. Firstly, AFGJ could induce mesenchymal stem cell (MSC) differentiation into vascular endothelial cells and the differentiated MSCs were involved in the tube formation. Secondly, Angio-G, the component derived from AFGJ, was able to stimulate significant proliferation of HUVECs in a dose dependent manner. Thirdly, in our tube-like capillary formation test of HUVECs in vitro, the length of formed tubes was greatly amplified with increasing concentration of Angio-G. Furthermore, the total length of Angio-G induced tubes was significantly reduced with increasing concentrations of AG490, an inhibitor of JAK/STAT pathways indicating possible involvement of the JAK/STAT signaling pathway. / Chen, Hao. / "December 2009." / Source: Dissertation Abstracts International, Volume: 72-01, Section: B, page: . / Thesis (Ph.D.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 136-145). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. Ann Arbor, MI : ProQuest Information and Learning Company, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.
|
Page generated in 0.0773 seconds